Mental wellness company Nue Life Health has announced the completion of its Series A equity financing led by Obvious Ventures.
Results from two-combined studies have revealed that psilocybin-assisted therapy increased brain activity in people with depression for up to three weeks following use.
Canadian-based Lophos Pharmaceuticals is engaging KGK Science to evaluate a path to market for sustainably-grown peyote-derived natural health products.
The first healthy, psychedelic-naïve volunteers have been dosed in Beckley Psytech’s Phase I clinical trial assessing safety and pharmacokinetics of its second innovative formulation of 5-MeO-DMT...
HMNC Brain Health and Develco Pharma have announced promising top-line results from the Phase II proof-of-concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01)...
Cybin Inc.
Leading UK psychedelics company Compass Pathways is entering into a pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate...
Data from Wesana Health indicates that administration of imipramine given three weeks following a psilocybin loading dose provided a 39 per cent improvement in depressive behaviours...
New research has suggested that sub-anaesthetic doses of ketamine could be beneficial for conditions such as post-traumatic stress disorder (PTSD), anxiety, addiction and eating disorders.
A systemic review of evidence has shown a lack of scientific research describing the interactions between widely used psychiatric medications and psychedelics like psilocybin and MDMA.